Navigation Links
KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Date:10/11/2007

EMERYVILLE, Calif., Oct. 11 /PRNewswire/ -- KineMed Inc., a pathway-based drug discovery and development company, announced today presentation of data demonstrating the ability of an investigational agent to regenerate nerve cells in the hippocampus, a part of the brain involved with cognition and mood. The agent, part of a partnered relationship in indications discovery, also improved performance in a behavioral test in a preclinical model. The findings were disclosed in a presentation titled, "Indications Discovery Using In Vivo Pathways as Targets," at the second annual Drug Repositioning Summit hosted by Cambridge Healthtech Institute in Philadelphia.

According to presenter Scott Turner, Ph.D., Vice President, Research at KineMed, "The KineMed team set out to demonstrate regenerative capacity in the hippocampus because all known anti-depressants stimulate hippocampal neurogenesis, and an increase in hippocampal neurogenesis correlates with improved learning and memory. Based on the reported findings, we believe we have identified a compound that could indeed have application in treating cognitive impairment, an area of substantial unmet clinical need."

David Fineman, President and CEO of KineMed, stated, "The current findings demonstrate the power of KineMed's technology, which measures the flow of molecules through intact metabolic pathways. Using this technology, KineMed is able to take a shelved compound, or an entire drug class, and put it back into the clinic, thereby derisking the class of compounds. This is unique from other efforts because our testing takes place in the intact human and animal. As described in the research presentation, we are able to demonstrate a compound's ability to increase hippocampal neurogenesis, providing a rationale for the compound's behavioral outcome."

Mr. Fineman added, "We are proud of the achievements of our team and look forward to further progress in these and other efforts."

Dr. Turner al
'/>"/>

SOURCE KineMed Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)...   Oligomerix, Inc. , a privately held company pioneering ... (AD) and related neurodegenerative disorders, announced today the relocation ... as of January 15, 2014 and expanded ... Medical College. Oligomerix, which is focused on ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Inc. today announced that the U.S. Food and Drug ... (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment ... by any diagnosed conditions of the uterus (womb), in ... With this approval, Natazia is the first and only ...
... March 14, 2012  Nile Therapeutics, Inc. (OTCQB: NLTX), ... heart failure patients, today announced the schedule of ... American College of Cardiology (ACC) 61th Scientific Session, ... Monday, March 26, 2012 Time: 10:00 AM -12:00 PM ...
Cached Medicine Technology:U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 2U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 3U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 4Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting 2
(Date:4/18/2014)... Medicine researchers have been awarded two-year grants for their ... this month. Of the 110 initial submissions to the ... Program, only four projects were funded, three of which ... Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias ... of oncology, will use his $500,000 proof of principle ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... researchers will lead a $10.25 million effort to study ... need for dialysis. The five-year project supports research ... that, though rare, generates an enormous individual and societal ... to nearly 12 percent of cases of kidney failure, ...
... , , , ... by wearing a purple LFA wristband until there is an FDA-approved medication ... It,s been 50 years since the U.S. Food and Drug Administration (FDA) ... President! To highlight the need for safer, more tolerable, and effective medications, ...
... NEW YORK, Sept. 22 The Global Network ... partnership with the Miss Universe Organization aimed at educating millions ... control and eliminate neglected tropical diseases across the region. ... time in their home countries participating in education and mass ...
... , , SAN MARCOS, Calif., ... NAII ), a leading formulator, manufacturer and marketer of customized nutritional ... per diluted share on net sales from continuing operations of $73.9 ... fiscal 2009 results include a net loss from discontinued operations of ...
... , , NEW YORK, Sept. 22 ... of specialty insurance and insurance-related products and services, will release 2009 third ... The news release will be available on Assurant,s Web site at ... broadcast its 2009 third quarter conference call at 9:00 a.m. ET on ...
... ELM GROVE, Wis., Sept. 22 A free ... Factor in HAI , is being sponsored by Compirion Healthcare Solutions, ... Wisconsin. Dates and times, along with registration information, can be found ... webinar are the main causes of non-compliance with hospital hand-washing ...
Cached Medicine News:Health News:Kidney advocates launch $10.25 million effort to examine cause of kidney failure 2Health News:The Lupus Foundation of America, Inc. Asks Supporters to Band Together for Lupus(SM) 2Health News:Miss Universe Organization, Global Network for Neglected Tropical Diseases Join Forces to Eliminate Neglected Tropical Diseases in the Americas 2Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 2Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 3Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 4Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 5Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 6Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 7Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 8Health News:Assurant to Announce 2009 Third Quarter Results Oct. 28, 2009 and Host Webcast Conference Call Oct. 29 2Health News:Free Webinar on Helping Hospitals Control Healthcare-Associated Infections by Improving Hand Hygiene 2Health News:Free Webinar on Helping Hospitals Control Healthcare-Associated Infections by Improving Hand Hygiene 3